Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 vs Entecavir in HBeAg-negative Chronic Hepatitis B
NCT05494528Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of ropeginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Undetectable HBsAg at 48 weeks. Status: unknown.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05494528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494528.